These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 1901508)
1. Hypokinesia, rigidity, and tremor induced by hypothalamic 6-OHDA lesions in the rat. Jolicoeur FB; Rivest R; Drumheller A Brain Res Bull; 1991 Feb; 26(2):317-20. PubMed ID: 1901508 [TBL] [Abstract][Full Text] [Related]
2. Antiparkinson-like effects of neurotensin in 6-hydroxydopamine lesioned rats. Jolicoeur FB; Rivest R; St-Pierre S; Drumheller A Brain Res; 1991 Jan; 538(2):187-92. PubMed ID: 1901504 [TBL] [Abstract][Full Text] [Related]
3. Structure-activity studies of neurotensin on muscular rigidity and tremors induced by 6-hydroxydopamine lesions in the posterolateral hypothalamus of the rat. Rivest R; St-Pierre S; Jolicoeur FB Neuropharmacology; 1991 Jan; 30(1):47-52. PubMed ID: 1904561 [TBL] [Abstract][Full Text] [Related]
4. Incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middle-aged rats. Lindner MD; Cain CK; Plone MA; Frydel BR; Blaney TJ; Emerich DF; Hoane MR Behav Brain Res; 1999 Jul; 102(1-2):1-16. PubMed ID: 10403011 [TBL] [Abstract][Full Text] [Related]
5. Differential behavioral activities from anterior and posterior hypothalamic lesions in the rat. Rondeau DB; Jolicoeur FB; Belanger F; Barbeau A Pharmacol Biochem Behav; 1978 Jul; 9(1):43-7. PubMed ID: 568291 [TBL] [Abstract][Full Text] [Related]
6. Effect of lesioning dopamine, noradrenaline and 5-hydroxytryptamine pathways on tremorine-induced tremor and rigidity. Dickinson SL; Slater P Neuropharmacology; 1982 Aug; 21(8):787-94. PubMed ID: 7121751 [TBL] [Abstract][Full Text] [Related]
7. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease. Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234 [TBL] [Abstract][Full Text] [Related]
8. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Henry B; Crossman AR; Brotchie JM Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768 [TBL] [Abstract][Full Text] [Related]
9. Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats. Buck K; Ferger B Neurobiol Dis; 2008 Feb; 29(2):210-20. PubMed ID: 17920284 [TBL] [Abstract][Full Text] [Related]
10. Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: behavioral and biochemical evidence. Cadet JL; Katz M; Jackson-Lewis V; Fahn S Brain Res; 1989 Jan; 476(1):10-5. PubMed ID: 2492442 [TBL] [Abstract][Full Text] [Related]
11. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease. Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870 [TBL] [Abstract][Full Text] [Related]
12. Effect of chronic apomorphine on the development of denervation supersensitivity. Robin M; Forler C; Palfreyman MG Pharmacol Biochem Behav; 1985 Apr; 22(4):547-51. PubMed ID: 3921992 [TBL] [Abstract][Full Text] [Related]
13. Intracerebroventricular administration of substance P increases dopamine content in the brain of 6-hydroxydopamine-lesioned rats. Krasnova IN; Bychkov ER; Lioudyno VI; Zubareva OE; Dambinova SA Neuroscience; 2000; 95(1):113-7. PubMed ID: 10619467 [TBL] [Abstract][Full Text] [Related]
14. 6-OHDA injections into A8-A9 dopaminergic neurons modelling early stages of Parkinson's disease increase the harmaline-induced tremor in rats. Kolasiewicz W; Kuter K; Berghauzen K; Nowak P; Schulze G; Ossowska K Brain Res; 2012 Oct; 1477():59-73. PubMed ID: 22902616 [TBL] [Abstract][Full Text] [Related]
15. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia. Kobylecki C; Crossman AR; Ravenscroft P Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800 [TBL] [Abstract][Full Text] [Related]
16. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease. Hossain MA; Weiner N J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772 [TBL] [Abstract][Full Text] [Related]
17. A potential target for the treatment of Parkinson's disease: effect of lateral habenula lesions. Han B; Jin HJ; Song MY; Wang T; Zhao H Parkinsonism Relat Disord; 2014 Nov; 20(11):1191-5. PubMed ID: 25219971 [TBL] [Abstract][Full Text] [Related]
19. Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease. Srinivasan J; Schmidt WJ Behav Brain Res; 2004 May; 151(1-2):191-9. PubMed ID: 15084435 [TBL] [Abstract][Full Text] [Related]
20. Neuroprotective effect of hydroxysafflor yellow A on 6-hydroxydopamine-induced Parkinson's disease in rats. Han B; Hu J; Shen J; Gao Y; Lu Y; Wang T Eur J Pharmacol; 2013 Aug; 714(1-3):83-8. PubMed ID: 23791614 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]